LONDON (Alliance News) - Summit Therapeutics PLC on Friday said new work showed a correlation between a reduction in a muscle damage biomarker and the use of its proposed treatment ezutromid.
Summit said analysis showed a high correlation between falls in myosin, which is an indicator of muscle damage, measured by muscle biopsy, and reductions of muscle inflammation.
This was observed in patients who had undergone 24 weeks of treatment with ezutromid.
The drug is a proposed treatment for muscular dystrophy, and Summit said the findings underpin existing evidence that by modulating utrophin protein production, ezutromid is reducing the severity of muscular dystrophy.
Chief Medical Officer & President of Research & Development David Roblin said: "The correlation observed between decreases in developmental myosin, a biomarker of muscle damage, and decreases in muscle fibre inflammation, is highly encouraging, and we believe further supports that ezutromid is breaking the DMD disease cycle of muscle damage and repair.
"We look forward to reporting the full results of this trial, expected in the third quarter of 2018."
Summit shares were up 6.0% on Friday at 204.00 pence each.
